Estimation of Imeglimin in Pharmaceutical Tablets by RP-HPLC

Shubham Jahagirdar, Rahul Godge^*, Sneha Vikhe, Snehal Bornare

PRES Pravara Rural College of Pharmacy, Loni, Maharashtra, India. 

Received: 26^th March, 2023; Revised: 10^th May, 2024; Accepted: 19^th May, 2024; Available Online: 25^th June, 2024 

ABSTRACT

Objective: This study’s primary goal is to create a novel, sensitive and comprehensive reverse phase-high performance liquid chromatography (RP-HPLC) procedure. The computation of Imeglimin’s dose and dosage is the primary goal.

Method: Chemicals and impurities were separated chromatographically using a C18 (AGILENT) chromatographic column. Methanol and 0.1% OPA are present in the mobile phase in a 40:60 v/v ratio. A 240 nm ultraviolet light detector was employed for the purpose of detection. With a retention time of 4.718 minutes, the results demonstrated the effectiveness of meglimin. After adjusting the flow rate to 0.7 mL/min, there was good separation. There are several imeglimin doses planned, ranging from 10 to 50 µg/mL. 101.46 to 101.12% in yield.

Results: This method’s validation has good accuracy, sensitivity, precision, linearity, specificity, and robustness, and it satisfies

the requirements of the International Conference on Harmonization.

Conclusion: In conclusion, imeglimin was predicted and the construction method was isolated. In conclusion, it’s feasible for daily use.

Keywords: Estimation, Imeglimin, RPHPLC, Validation.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.19

How to cite this article: Jahagirdar S, Godge R, Vikhe S, Bornare S. Estimation of Imeglimin in Pharmaceutical Tablets by RP-HPLC. International Journal of Drug Delivery Technology. 2024;14(2):724-726.

REFERENCES

1. International Diabetic Federation for Type 2. Available from: http://www.idf.org/aboutdiabetes/type-2diabetes. [Last accessed on 31 Oct 2023]
2. Hallakou BS, Vial G, Kergoat M. Mechanism of action of imeglimin: a novel therapeutic agent for type 2 Diabetes Obes Metab. 2021;23(3):664-73. DOI: 10.1111/dom.14277, PMID 33269554.
3. Hallakou BS, Kergoat Imeglimin preserves islet β-cell mass in type 2 diabetic ZDF rats. Endocrinol Diabetes Metab. 2021;4(2): e00193. DOI: 10.1002/edm2.193, PMID 33855202.
4. Olokoba AB, Obateru Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27(4):269-73. DOI: 10.5001/ omj.2012.68, PMID 23071876.
5. Introduction to diabetes. Available from: https://www.healthline. com/health/diabetes.
6. Sathawane YJ, T ha kare Development of Novel UV-Spectrophotometric Method for Imeglimin Hydrochloride. International Journal of Pharmaceutical Research and Applications.2023; 8(3):1637-1644. DOI: 10.35629/7781-080316371644
7. Tamil SR. Research A Novel Method Development and Validation of Imeglimin HCl by Visible Spectroscopy. Int. J. in Sci. 2023; 1(12): 852-859. DOI: 10.5281/zenodo.10433883
8. Jain A, Sharma R. Development and Validation of Stability Indicating Rp-UHPLC method for the estimation of imeglimin hydrochloride used for the treatment of Metabolic Disorder Diabetes Mellitus. Int. J. App Pharm. 2023; 15(6): 211-217.
9. Salvi AS, Khamkar Development and Validation of RP-HPLC Method for Estimation of Anti-Diabetic Drug in Bulk and Tablet Dosage Form. Journal of Emerging Technologies and Innovative Research. 2023; 10(5): h366-h378.
10. Patil DJ, Godge RK, Jahagirdar SN, Mandhare SB. Validated Stability Indicating RP-HPLC Method for the Quantification of Process Related Impurities of Solifenacin and Mirabegron in Pharmaceutical Formulations. International Journal of Drug Delivery Technology. 2024;14(1):55-60.